Home › Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
 

Keywords :   


Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes

2014-02-10 14:43:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Language: English Contact: Merck Media InquiriesKim Hamilton, 908-423-6831orCaroline Lappetito, 267-305-7639orMerck Investor RelationsCarol Ferguson, 908-423-4465orSamsung Media InquiriesHongSeok Ji, +82-32-455-6102orSamsung Investor RelationsSungjoon Park, +82-32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for enter agreement develop

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.06Wrap sold in WH Smith recalled over E. coli fears
17.06Atlantic Tropical Weather Outlook
17.06Eastern North Pacific Tropical Weather Outlook
17.06Pixar's Inside Out 2 sees record opening weekend
17.06Atlantic Tropical Weather Outlook
17.06Eastern North Pacific Tropical Weather Outlook
17.06Too much of a good thing? Spain's green energy can exceed demand
16.06Eastern North Pacific Tropical Weather Outlook
More »